高级检索
    李大珊, 邓玲, 葛洪峰, 朱俊峰, 王玲, 史玉叶, 张颢, 沈子园, 桑威, 淮海淋巴瘤协作组. EASIX在弥漫大B细胞淋巴瘤中的预后价值评估:一项淮海淋巴瘤协作组的多中心回顾性研究[J]. 徐州医科大学学报, 2024, 44(1): 47-54. DOI: 10.3969/j.issn.2096-3882.2024.01.009
    引用本文: 李大珊, 邓玲, 葛洪峰, 朱俊峰, 王玲, 史玉叶, 张颢, 沈子园, 桑威, 淮海淋巴瘤协作组. EASIX在弥漫大B细胞淋巴瘤中的预后价值评估:一项淮海淋巴瘤协作组的多中心回顾性研究[J]. 徐州医科大学学报, 2024, 44(1): 47-54. DOI: 10.3969/j.issn.2096-3882.2024.01.009
    LI Dashan, DENG Ling, GE Hongfeng, ZHU Junfeng, WANG Ling, SHI Yuye, ZHNAG Hao, SHEN Ziyuan, SANG Wei, Huaihai Lymphoma Working Group. Assessment of the prognostic value of EASIX in diffuse large B-cell lymphoma: A multicenter retrospective study of Huaihai Lymphoma Working Group[J]. Journal of Xuzhou Medical University, 2024, 44(1): 47-54. DOI: 10.3969/j.issn.2096-3882.2024.01.009
    Citation: LI Dashan, DENG Ling, GE Hongfeng, ZHU Junfeng, WANG Ling, SHI Yuye, ZHNAG Hao, SHEN Ziyuan, SANG Wei, Huaihai Lymphoma Working Group. Assessment of the prognostic value of EASIX in diffuse large B-cell lymphoma: A multicenter retrospective study of Huaihai Lymphoma Working Group[J]. Journal of Xuzhou Medical University, 2024, 44(1): 47-54. DOI: 10.3969/j.issn.2096-3882.2024.01.009

    EASIX在弥漫大B细胞淋巴瘤中的预后价值评估:一项淮海淋巴瘤协作组的多中心回顾性研究

    Assessment of the prognostic value of EASIX in diffuse large B-cell lymphoma: A multicenter retrospective study of Huaihai Lymphoma Working Group

    • 摘要: 目的 探讨内皮活化和应激指数(EASIX)对初诊弥漫大B细胞淋巴瘤(DLBCL)患者预后的价值。方法 选取2008年8月-2022年3月在淮海淋巴瘤协作组中6家医疗中心诊断为DLBCL的580例患者,收集临床资料进行回顾性分析。基于MaxStat统计量确定EASIX的最佳截断值。使用Cox比例风险模型进行单因素和多因素分析,确定影响DLBCL患者生存结局的变量。使用Kaplan-Meier生存曲线进行预后分析。结果 580例患者中男性294例(50.7%),中位年龄(60.32±13.36)岁,总体5年OS率为56.4%。基于MaxStat统计量计算出EASIX的最佳截断值为1.17。多因素分析显示EASIX、年龄、血红蛋白、中枢累及、Ann Arbor分期是DLBCL患者的独立危险因素(P<0.05)。亚组分析结果表明,EASIX可以对BCL-2-和BCL-2+组、BCL-6-和BCL-6+组、GCB和非GCB组、ECOG PS评分<2分和 ≥ 2分组、Ann Arbor Ⅰ/Ⅱ期和Ⅲ/Ⅳ期、IPI评分LR/LIR和HIR/HR组以及NCCN-IPI评分LR/LIR和HIR/HR组的患者进行预后再分层。结论 高EASIX(>1.17)与初诊DLBCL患者的不良预后有关,且EASIX能对不同亚组的患者进行准确的预后分层。

       

      Abstract: Objective To investigate the prognostic value of endothelial activation and stress index (EASIX) for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL).Methods A total of 580 patients who were diagnosed with DLBCL in six medical centers in Huaihai Lymphoma Working Group from August 2008 to March 2022 were selected and their clinical data were retrospectively analyzed. The MaxStat algorithm was used to determine the optimal cut-off value of EASIX. The Cox proportional hazard regression model was used for univariate and multivariable analysis to determine the variables influencing the survival outcomes of DLBCL patients. Kaplan-Meier survival curves were plotted for prognostic analysis, and the differences between groups were tested by log-rank.Results There were 294 men among the 580 patients(50.7%). The median age was (60.32±13.36) years, and the overall 5-year OS rate was 56.4%. Through MaxStat statistics, the optimal cut-off value of EASIX was 1.17. Multivariable analysis indicated that EASIX, age, hemoglobin, central involvement and Ann Arbor stage were the independent risk factors for DLBCL patients (P<0.05). The results of subgroup analysis showed that EASIX-based re-stratification was suitable for evaluating the prognosis of patients in the BCL-2- and BCL-2+ groups, the BCL-6- and BCL-6+ groups, the GCB and non-GCB groups, the ECOG PS < 2 and ≥ 2 groups, the Ann Arbor stages Ⅰ/Ⅱ and Ⅲ/Ⅳ, the IPI score LR/LIR and HIR/HR groups, and the NCCN-IPI score LR/LIR and HIR/HR groups.Conclusions High EASIX(>1.17) is associated with poor prognosis for patients newly diagnosed with DLBCL, and EASIX can accurately stratify the prognosis of patients in different subgroups.

       

    /

    返回文章
    返回